Monitor for the closing of the NYB-RFAI business combination and any subsequent valuation disclosure for The9's stake. The listing could provide a public market valuation for The9's investment, but the impact is contingent on deal completion and market reception of NYB shares.
Price Chart
Executive Summary
The9 announced that its investee, Nanyang Biologics (NYB), has cleared a key milestone toward a Nasdaq listing after RFAI shareholders voted to approve the business combination. The9 expects to hold approximately 15% to 16% of the combined Nasdaq-listed company. This is a positive development for The9's strategic investment in AI-driven drug discovery, but the deal remains subject to customary closing conditions and no financial terms or valuation were disclosed.
Key Facts
- RFAI shareholders voted to approve NYB's proposed business combination on August 19, 2026.
- The9 expects to hold approximately 15% to 16% of the combined Nasdaq-listed company.
- NYB is a Singapore-based AI-driven drug discovery company with a Vecura AI platform.
- The business combination remains subject to customary closing conditions.
- No financial terms, valuation, or timeline for the closing were disclosed.
Financial Impact
The9 expects to hold approximately 15% to 16% of the combined Nasdaq-listed company; no dollar value or valuation disclosed.
Risk Factors
- The business combination remains subject to customary closing conditions and may not be completed.
- No financial terms or valuation were disclosed, making it difficult to assess the materiality of the stake.
- The9's core gaming and crypto businesses face regulatory and market risks that could overshadow this investment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-099420 |
| Document: tm2623773d1_6k.htm | 0001104659-26-099420 |
| Document: 0001104659-26-099420-index-headers.html | 0001104659-26-099420 |
| Document: 0001104659-26-099420-index.html | 0001104659-26-099420 |
| Document: 0001104659-26-099420.txt | 0001104659-26-099420 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 6-K | $3.34 $3.39 | ▲ +1.50% | ▲ +1.68% | $3.28 (−1.80%) |
Aug 24, 2026 9w ago | 6-K | $5.57 $4.37 | ▲ +21.54% | ▲ +21.86% | $3.28 (+41.11%) |
Aug 21, 2026 9w ago | 6-K | $5.78 $5.57 | ▼ −3.63% | ▼ −3.34% | $3.28 (−43.25%) |
Aug 6, 2026 11w ago | 6-K | $5.01 $4.71 | ▼ −5.99% | ▼ −6.60% | $3.28 (−34.53%) |
Jul 27, 2026 13w ago | 6-K | $4.54 $4.62 | ▼ −1.76% | ▼ −1.52% | $3.28 (+27.75%) |
Jul 27, 2026 13w ago | Press Release | $4.54 $4.62 | ▲ +1.76% | ▲ +1.52% | $3.28 (−27.75%) |
Jul 21, 2026 13w ago | EFFECT | $3.98 $3.96 | ▼ −0.63% | ▼ −0.51% | $3.28 (−17.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers